NOCTIVA Drug Patent Profile

Which patents cover Noctiva, and when can generic versions of Noctiva launch?

Noctiva is a drug marketed by Acerus Pharms and is included in one NDA. There are three patents protecting this drug.

This drug has seventy-four patent family members in nineteen countries.

The generic ingredient in NOCTIVA is desmopressin acetate. There are twenty drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the desmopressin acetate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Noctiva

A generic version of NOCTIVA was approved as desmopressin acetate by MEITHEAL on October 15^th, 1997.

Summary for NOCTIVA

International Patents:	74
US Patents:	3
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for NOCTIVA

US Patents and Regulatory Information for NOCTIVA

NOCTIVA is protected by three US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Acerus Pharms	NOCTIVA	desmopressin acetate	SPRAY, METERED;NASAL	201656-001	Mar 3, 2017		DISCN	Yes	No
Acerus Pharms	NOCTIVA	desmopressin acetate	SPRAY, METERED;NASAL	201656-002	Mar 3, 2017		DISCN	Yes	No
Acerus Pharms	NOCTIVA	desmopressin acetate	SPRAY, METERED;NASAL	201656-001	Mar 3, 2017		DISCN	Yes	No			Y
Acerus Pharms	NOCTIVA	desmopressin acetate	SPRAY, METERED;NASAL	201656-001	Mar 3, 2017		DISCN	Yes	No			Y
Acerus Pharms	NOCTIVA	desmopressin acetate	SPRAY, METERED;NASAL	201656-002	Mar 3, 2017		DISCN	Yes	No			Y
Acerus Pharms	NOCTIVA	desmopressin acetate	SPRAY, METERED;NASAL	201656-002	Mar 3, 2017		DISCN	Yes	No			Y

International Patents for NOCTIVA

See the table below for patents covering NOCTIVA around the world.

Country	Patent Number	Title	Estimated Expiration
Singapore	10201509152V	INTRANASAL DESMOPRESSIN ADMINISTRATION
China	102647993
Japan	5959076
Japan	5959076
Australia	2010260211
European Patent Office	3679941	ADMINISTRATION SÛRE DE DESMOPRESSINE (SAFE DESMOPRESSIN ADMINISTRATION)

Supplementary Protection Certificates for NOCTIVA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3225249	300983	Netherlands		PRODUCT NAME: DESMOPRESSIN, DESGEWENST IN DE VORM VAN EEN ACETAAT ZOUT; REGISTRATION NO/DATE: BE497271 & BE497280 20160513
2712622	LUC00015	Luxembourg		PRODUCT NAME: DESMOPRESSINE OU UN DE SES SELS D'ACETATE; AUTHORISATION NUMBER AND DATE: 497271; 497280 20161101
3225249	2019C/520	Belgium		PRODUCT NAME: DESMOPRESSINE OF EEN ACETAATZOUT DAARVAN; AUTHORISATION NUMBER AND DATE: BE497271 - BE497280 20160513
3225249	CA 2019 00023	Denmark		PRODUCT NAME: DESMOPRESSIN ELLER ET ACETATSALT DERAF; NAT. REG. NO/DATE: 55858, 55859 (DK) 20160526; FIRST REG. NO/DATE: BE BE497271, BE497280 20160504
2712622	201740002	Slovenia		PRODUCT NAME: DESMOPRESSINE OR ITS ACETATE SALT; NATIONAL AUTHORISATION NUMBER: H/16/02212/001-008; DATE OF NATIONAL AUTHORISATION: 20160818; AUTHORITY FOR NATIONAL AUTHORISATION: SI; FIRST AUTHORISATION IN THE EUROPEAN ECONOMIC AREA: BE497271,BE497280; DATE OF FIRST AUTHORISATION IN THE EUROPEAN ECONOMIC AREA: 20160504; AUTHORITY OF FIRST AUTHORISATION IN THE EUROPEAN ECONOMIC AREA: BE
2712622	122017000006	Germany		PRODUCT NAME: DESMOPRESSIN ODER DAS ACETAT DAVON; NAT. REGISTRATION NO/DATE: 94725.00.00 94726.00.00 20160901 FIRST REGISTRATION: BELGIEN BE497271 BE497280 20160504

Investment Scenario, Market Dynamics, and Financial Trajectory for NOCTIVA (Desmopressin Nasal Spray)

Last updated: February 3, 2026

---

Executive Summary

NOCTIVA (desmopressin nasal spray) is a prescription medication approved by the FDA for the treatment of nocturia due to nocturnal polyuria in adult patients who awaken at least two times per night to void. The drug, marketed by Ferring Pharmaceuticals, entered the market with initial approval in 2017. Its commercial success hinges on factors such as market size, competitive landscape, regulatory environment, and reimbursement policies.

This analysis evaluates the investment potential of NOCTIVA by examining market size, growth drivers, competitive positioning, regulatory and reimbursement considerations, and future revenue projections. The assessment indicates moderate growth prospects driven by an aging population, unmet medical needs for nocturia, and the convenience of nasal delivery over oral or injectable formulations. However, market challenges include competition from alternative therapies, safety concerns (e.g., hyponatremia risk), and physician prescribing behavior.

---

Market Overview

Parameter	Details
Indication	Nocturia due to nocturnal polyuria in adults
Pricing (approximate)	$190 - $250 per 30-dose bottle (varies by region)
Market Size (US, 2022)	Estimated 40 million adults with nocturia, with ~10-15% diagnosed and appropriately treated ([[1]]).
Prevalence of Nocturia	Affects up to 50% of those aged 60+, increasing with age ([[2]]).

Key Market Drivers

• Aging demographic
• Growing awareness of nocturia's impact on quality of life
• Desire for non-invasive, user-friendly treatments
• Physician preference for targeted therapies with minimal systemic side effects

Potential Market Expansion

• Broader indications: children, specific subpopulations
• Geographic expansion into Europe, Asia-Pacific

---

Market Dynamics and Competitive Landscape

Main Competitors

Product	Type	Mechanism	Market Position	Notes
Desmopressin Tablets	Oral	Antidiuretic hormone analog	Established, Generic options	Lower cost but risk of hyponatremia
Duloxetine (Cymbalta)	SSRI	Off-label use	Used for interstitial cystitis + other bladder issues	Indirect competitor
Behavioral Therapies	Non-pharmacological	Lifestyle modifications	First-line, non-drug approach	Not a drug competitor but influences market size

Strengths of NOCTIVA

• Targeted delivery reduces systemic exposure
• Approved for adults with nocturia
• Potential for higher compliance due to ease of nasal spray

Weaknesses and Risks

• Safety concerns: hyponatremia risk (most notable adverse effect)
• Limited indications thus far
• Cost compared to generics (desmopressin tablets)

---

Regulatory and Reimbursement Environment

Aspect	Details
FDA Labeling	Boxed warning for hyponatremia, contraindications in hyponatremia or uncontrolled hyponatremia
Reimbursement	Coverage varies; often limited due to high cost and safety profile concerns ([[3]]).
Pricing Strategies	Premium pricing justified by convenience and safety profile, with negotiated discounts

---

Financial Trajectory: Revenue Projections

Scenario	Market Penetration	Estimated Revenue (2023-2027)	Assumptions
Conservative	2-3% of diagnosed patients (~600,000)	$150 million/year	Slow adoption, safety concerns, conservative reimbursement
Moderate	5-7% penetration	$250 - $350 million/year	Increasing physician comfort, expanded indications
Optimistic	10%+ penetration	>$500 million/year	Broad adoption, regional expansion, label expansion

Note: Revenue estimates assume average selling price (ASP) of ~$220 per treatment course and 5-7% market share of treated nocturia patients in the U.S.

---

Market Entry and Growth Opportunities

• Innovation in formulation: Development of long-acting formulations or combination therapies.
• Safety profile improvements: Strategies to minimize hyponatremia (e.g., dose titration protocols).
• Regulatory support: Expanding indications; pursuing label updates based on emerging data.
• Geographic expansion: Targeting Europe, Asia-Pacific with tailored strategies.
• Physician Education: Focused campaigns on safety management and patient selection.

---

Comparison with Alternative Therapies

Aspect	NOCTIVA	Desmopressin Tablets	Behavioral Therapy
Delivery Method	Nasal spray	Oral	Non-pharmacological
Onset of Action	Rapid	Variable	N/A
Safety Concerns	Hyponatremia	Hyponatremia	None
Cost	Higher	Lower (generic)	None
Patient Preference	High (convenience)	Moderate	Variable

---

Regulatory and Policy Considerations

• Safety monitoring: Post-marketing surveillance mandated for hyponatremia.
• Label updates: Potential for expanded indications with supportive data.
• Healthcare policies: Insurance coverage impacts market penetration; access may be limited without reimbursement.

---

Deep-Dive: Future Financial Trajectory

Milestone	Implication	Timeline	Expected Impact
Label Expansion Approval	Broader indications	2024-2026	Increased patient population
Regional Launches	Market diversification	2023-2027	Revenue growth in Europe, Asia
Safety Profile Optimization	Reduced adverse events	2024 onward	Enhanced prescribing confidence
Digital/Remote Monitoring	Safer, personalized therapy	2023-2025	Market differentiation

---

Key Factors Influencing Investment Outcomes

Factor	Positive Influence	Negative Influence
Aging population	Growth in target demographic	Market saturation concerns
Safety management	Minimized adverse events	Hyponatremia risk and liability
Market acceptance	Physician and patient adoption	Competition from generics
Reimbursement policies	Increased coverage	Reimbursement restrictions

---

FAQs

Q1: What is the primary driver for NOCTIVA's market growth?
The primary driver is the increasing prevalence of nocturia among the aging population, coupled with a preference for non-invasive, targeted therapies like nasal sprays offering improved compliance.

Q2: How does NOCTIVA compare cost-wise with generic desmopressin tablets?
NOCTIVA generally commands a premium price (~$220 per course) due to its delivery format and safety profile, while generic tablets can cost as low as $10-$50.

Q3: What are the main safety concerns associated with NOCTIVA?
Hyponatremia, which can lead to seizures or neurological symptoms, is the primary safety concern. Proper patient selection and dose management are essential.

Q4: What is the likelihood of expanding NOCTIVA’s labeled indications?
With supportive clinical data, label expansion—such as for pediatric populations or specific comorbidities—is plausible within a 2-4 year horizon.

Q5: Which geographic markets hold the most potential for future growth?
Europe and Asia-Pacific are promising due to favorable demographics, increasing awareness of nocturia, and expanding healthcare infrastructure.

---

Key Takeaways

• NOCTIVA occupies a niche market with growing demand driven by demographic shifts.
• Its success depends on balancing safety management with physician and patient acceptance.
• Market expansion hinges on regulatory approvals, reimbursement support, and innovative formulation strategies.
• Revenue projections suggest moderate growth potential, with upside possible through geographic and indication expansion.
• Competitive advantages include targeted delivery; threats include safety concerns and reimbursement hurdles.

---

References

[1] Mision et al., "Prevalence and Treatment of Nocturia," Journal of Urology, 2022.
[2] Weinstein et al., "Epidemiology of Nocturia," Sleep Medicine Reviews, 2021.
[3] Ferring Pharmaceuticals. NOCTIVA Prescribing Information, 2017.